April 8, 2019 / Last updated : April 8, 2019 Benjamin Clark Pharmaceuticals

Johnson & Johnson Valuation – April 2019 #JNJ

Johnson & Johnson does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, insufficient earnings growth over the last ten years, and the high PEmg and PB ratios.

April 2, 2019 / Last updated : April 2, 2019 Benjamin Clark Pharmaceuticals

Bristol-Myers Squibb Co Valuation – April 2019 #BMY

Bristol-Myers Squibb Co is suitable for the Enterprising Investor but not the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, high PB ratio.

March 28, 2019 / Last updated : March 28, 2019 Benjamin Clark Pharmaceuticals

Biogen Inc Valuation – March 2019 #BIIB

Biogen Inc qualifies for both the Defensive Investor and the Enterprising Investor. The Defensive Investor is only initially concerned with the poor dividend history.

March 27, 2019 / Last updated : March 27, 2019 Benjamin Clark Pharmaceuticals

Mylan NV Valuation – March 2019 #MYL

Mylan NV does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, poor dividend history.

March 25, 2019 / Last updated : March 25, 2019 Benjamin Clark Pharmaceuticals

Celgene Corp Valuation – March 2019 #CELG

Celgene Corporation does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the poor dividend history, and the high PB ratio.

March 24, 2019 / Last updated : March 24, 2019 Benjamin Clark Pharmaceuticals

Amgen Inc Valuation – March 2019 #AMGN

Amgen, Inc. is suitable for the Enterprising Investor but not the more conservative Defensive Investor. The Defensive Investor is concerned with the poor dividend history, and the high PB ratio.

March 3, 2019 / Last updated : March 3, 2019 Benjamin Clark Pharmaceuticals

AbbVie Inc Valuation – March 2019 #ABBV

AbbVie Inc does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, insufficient earnings stability over the last ten years, and the poor dividend history, and the high PB ratio.

February 25, 2019 / Last updated : February 25, 2019 Benjamin Clark Pharmaceuticals

Allergan PLC Valuation – February 2019 $AGN

Allergan plc does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, insufficient earnings stability or growth over the last ten years, and the poor dividend history, and the high PEmg ratio.

February 19, 2019 / Last updated : February 19, 2019 Benjamin Clark Pharmaceuticals

Incyte Corp Valuation – February 2019 $INCY

Incyte Corporation does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the insufficient earnings stability or growth over the last ten years, and the poor dividend history, and the high PEmg and PB ratios.

February 19, 2019 / Last updated : February 19, 2019 Benjamin Clark Pharmaceuticals

Regeneron Pharmaceuticals Inc Valuation – February 2019 $REGN

Regeneron Pharmaceuticals Inc is suitable for the Enterprising Investor but not the more conservative Defensive Investor. The Defensive Investor is concerned with the insufficient earnings stability over the last ten years, and the poor dividend history, and the high PEmg and PB ratios.